We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · February 25, 2021

Predicted Sensitivity to Endocrine Therapy for Stage II–III HR-Positive and HER2-Negative Breast Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Predicted Sensitivity to Endocrine Therapy for Stage II-III Hormone Receptor-Positive and HER2-Negative (HR+/HER2-) Breast Cancer Prior to Chemo-Endocrine Therapy
Ann. Oncol 2021 Feb 19;[EPub Ahead of Print], L Du, C Yau, L Brown-Swigart, R Gould, G Krings, GL Hirst, I Bedrosian, RM Layman, JM Carter, M Klein, S Venters, S Sonal, M van der Noordaa, AJ Chien, T Haddad, C Isaacs, L Pusztai, K Albain, R Nanda, D Tripathy, MC Liu, J Boughey, R Schwab, N Hylton, A DeMichele, J Perlmutter, D Yee, D Berry, L van’t Veer, V Valero, L Esserman, WF Symmans

Further Reading